SCHEMBL859834

SCHEMBL859834

C[Si](C)(C)c1nnn(-c2cccc3ccccc23)c1SCC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 8/20 0.48
▸ HSD17B10 Q99714 1/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ MEN1 O00255 5/20 0.44
▸ KMT2A Q03164 5/20 0.44
▸ POLB P06746 2/20 0.42
▸ FFAR1 O14842 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MAPK1 P28482 1/20 0.39
▸ USP2 O75604 1/20 0.39
▸ CYP1A2 P05177 3/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ HTT P42858 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ ADRB2 P07550 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL859723 0.86 ALDH1A1 (0.66) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL859415 0.76 ALDH1A1 (0.74) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL10177198 0.70 TSHR (0.53) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL4736086 0.68 SLC22A12 (0.69) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL20604102 0.67 HTT (0.61) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL4736083 0.65 CYP1A2 (0.48) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL13547675 0.65 ALDH1A1 (0.76) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL3077714 0.65 MEN1 (0.61) ALDH1A1HSD17B10HPGDMEN1KMT2A
SCHEMBL1493532 0.64 HSD11B1 (0.54) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD
SCHEMBL5958904 0.64 ALDH1A1 (0.53) ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372807-B2 Methods of modulating uric acid levels ARDEA BIOSCIENCES, INC. (US) 2013-02-12 — — US disclosed
US-20120135929-A1 Methods Of Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-31 — — US disclosed
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels ARDEA BIOSCIENCES INC. (US) 2012-05-17 — — US disclosed
EP-2432774-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS Ardea Biosciences, Inc. (US) 2012-03-28 — — EP disclosed
EP-2432468-A2 METHODS OF MODULATING URIC ACID LEVELS Ardea Biosciences, Inc. (US) 2012-03-28 — — EP disclosed
WO-2010135536-A2 METHODS OF MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 — — WO disclosed
WO-2010135530-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS ARDEA BIOSCIENCES, INC. (US) 2010-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122780-A1 Compounds, Compositions and Methods for Modulating Uric Acid Levels XDH, PON1, RBP4 ALDH1A1 188/4885HSD17B10 1242/4885SMN1; SMN2 1435/4885
US-20120135929-A1 Methods Of Modulating Uric Acid Levels XDH, PON1, OAT ALDH1A1 167/4885HSD17B10 1635/4885SMN1; SMN2 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback